作者
Andres F. Espinoza,Roma H. Patel,Kalyani R. Patel,Andrew Badachhape,Richard S. Whitlock,Rohit Srivastava,Saiabhiroop R. Govindu,Allen Duong,Abhishek Kona,Pavan Kureti,Bryan W. Armbruster,Dina Kats,Ramakrishnan Rajaram Srinivasan,Lacey E. Dobrolecki,Xinjian Yu,Mohammad Javad Najaf Panah,Barry Zorman,Stephen F. Sarabia,Martin Urbicain,Angela Major,Karl‐Dimiter Bissig,Charles Keller,Michael T. Lewis,Andras Heczey,Pavel Sumazin,Dolores López‐Terrada,Sarah E. Woodfield,Sanjeev A. Vasudevan
摘要
Patients with metastatic, treatment-refractory, and relapsed hepatoblastoma (HB) have survival rates of less than 50% due to limited treatment options. To develop new therapeutic strategies for these patients, our laboratory has developed a preclinical testing pipeline. Given that histone deacetylase (HDAC) inhibition has been proposed for HB, we hypothesized that we could find an effective combination treatment strategy utilizing HDAC inhibition.